Funding
Series A · AI

Converge Bio raises $25M Series A

Converge Bio raised $25 million in Series A financing announced in January.

Updated Oct 16, 2026By RoundOS Funding desk

Bessemer Venture Partners, TLV Partners, Vintage Investment Partners and Saras Capital are among its backers. The company develops AI tools for drug discovery and development.

Funding history

Series A · This round$25M

Sources

  1. Converge Bioprojectstartups.com
  2. prnewswire.com

Similar rounds

All AI rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Knowledge Work

Tokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.

¥4.8BSeries C debt second close · Oct 23, 2026

Related